Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.84 HKD
Change Today +0.02 / 2.44%
Volume 90.0K
As of 3:01 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

shenzhen neptunus interlng-h (8329) Snapshot

Open
$0.82
Previous Close
$0.82
Day High
$0.84
Day Low
$0.82
52 Week High
03/11/14 - $1.50
52 Week Low
03/7/14 - $0.61
Market Cap
1.4B
Average Volume 10 Days
231.0K
EPS TTM
$0.02
Shares Outstanding
426.0M
EX-Date
--
P/E TM
38.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for SHENZHEN NEPTUNUS INTERLNG-H (8329)

Related News

No related news articles were found.

shenzhen neptunus interlng-h (8329) Related Businessweek News

No Related Businessweek News Found

shenzhen neptunus interlng-h (8329) Details

Shenzhen Neptunus Interlong Bio-Technique Company limited is engaged in the research and development, production, sale, and distribution of gene engineering drugs and preventive biological products in the People’s Republic of China. It offers herbal medicines, generic drugs, and transfusion and anti-tumor drugs under the Neptunus or Interlong brands. The company’s products include INTERLONG Recombinant Human Interferon a-2b for injection to treat viral diseases, including acute and chronic hepatitis, herpes zoster, and condylomata acuminate, as well as tumors comprising hairy cell leukemia, chronic myelocytic leukemia, multiple myeloma, non-Hodgkin’s lymphomas, malignant melanoma, kidney cell cancer, laryngeal papilloma, kaposis sarcoma, oophoroma, basal cell carcinoma, and bladder cancer. It also provides INTERKING Recombinant Human Interleukin-2 (125 Ser) for injection to treat renal cell carcinoma, melanoma, breast carcinoma, bladder cancer, liver carcinoma, rectal cancer, lymphoma, lung cancer, and carcinomatous thoracico-ascites; and supplementary treatment of tumor, congenital and acquired immune deficiency, autoimmune diseases, and chronic infections. In addition, the company is involved in the production of chemical medicine; sale and distribution of healthcare food, medicines, and healthcare products; and wholesale and retail of packaging materials and pre-packaged food. Shenzhen Neptunus Interlong Bio-Technique Company limited sells its products in approximately 20 provinces in the People’s Republic of China, as well as serves approximately 500 medical organizations. The company is based in Admiralty, Hong Kong. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Co., Ltd.

1,410 Employees
Last Reported Date: 03/31/14

shenzhen neptunus interlng-h (8329) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: CNY632.0K
Executive Chairman, Compliance Officer, Chair...
Total Annual Compensation: --
Executive Director
Total Annual Compensation: CNY480.0K
Compensation as of Fiscal Year 2013.

shenzhen neptunus interlng-h (8329) Key Developments

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Enters into Distribution Agreement with Neptunus Jiankang

Reference is made to the announcement of the Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. dated 24 July 2012 in relation to, among other things, the continuing connected transactions under the Existing Jiankang Distribution Agreement entered into between the Company and Neptunus Jiankang, a fellow subsidiary and a connected person of the Company, pursuant to which the Company agreed to purchase and distribute various healthcare food products and food products manufactured by Neptunus Jiankang. The Existing Jiankang Distribution Agreement will expire on 31 December 2014. On 17 December 2014, the Company and Neptunus Jiankang entered into the Renewed Jiankang Distribution Agreement for a further term of three years from 1 January 2015 to 31 December 2017 to renew the distribution arrangements. The Term is from 1 January 2015 to 31 December 2017, unless terminated by either party as a result of the breach by the other party under the Renewed Jiankang Distribution Agreement. The purchase prices for the products will be settled by the Group within sixty (60) days after (i) the date of the issue of the invoice by Neptunus Jiankang or (ii) the receipt of the products by the Group, whichever is earlier.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's turnover was RMB 162,077,000 compared with RMB 159,028,000 a year ago. Profit from operations was RMB 17,107,000 compared with RMB 11,705,000 a year ago. Profit before taxation was RMB 14,232,000 compared with RMB 9,611,000 a year ago. Profit attributable to owners of the company was RMB 7,924,000 or 0.47 cents per basic and diluted share compared with RMB 4,745,000 or 0.28 cents per basic and diluted share a year ago. For the nine months, the company's turnover was RMB 478,346,000 compared with RMB 456,889,000 a year ago. Profit from operations was RMB 63,430,000 compared with RMB 51,672,000 a year ago. Profit before taxation was RMB 55,287,000 compared with RMB 46,037,000 a year ago. Profit attributable to owners of the company was RMB 32,063,000 or 1.91 cents per basic and diluted share compared with RMB 38,089,000 or 2.27 cents per basic and diluted share a year ago. The increase in turnover was mainly due to two reasons: affected by the new GMP certification of Neptunus Jinxiang and since the production and sales of small-dose injections of Neptunus Fuyao were in the phase of recovery, the turnover of Neptunus Fuyao and its subsidiaries decreased slightly in the first quarter of this year. However along with the elimination of such effects, turnover from Neptunus Fuyao and its subsidiaries increased steadily starting from the second quarter of this year; and turnover of Neptunus Changjian during the Relevant Period increased compared with that of the corresponding period last year. The profit attributable to the owners of the Company decreased mainly because Neptunus Fuyao was affected by the adjustment of tax rate of the PRC enterprise income tax during last year, which resulted in the decrease in deferred tax liabilities of approximately RMB 13,966,000.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. to Report Q3, 2014 Results on Nov 07, 2014

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. announced that they will report Q3, 2014 results on Nov 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8329:HK $0.84 HKD +0.02

8329 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8329.
View Industry Companies
 

Industry Analysis

8329

Industry Average

Valuation 8329 Industry Range
Price/Earnings 36.5x
Price/Sales 1.7x
Price/Book 2.2x
Price/Cash Flow 36.5x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHENZHEN NEPTUNUS INTERLNG-H, please visit www.interlong.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.